Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05266313
Other study ID # 21_RIPH2-06
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 31, 2022
Est. completion date March 31, 2025

Study information

Verified date October 2023
Source University Hospital Center of Martinique
Contact Céline MINCHACA-PERROCHAUD
Phone 05.96.48.88.60
Email celine-minchaca@chu-martinique.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The paramedic urology team at Martinique University Hospital has developed a "personalized rehabilitation oncosexology program for patients undergoing radical prostatectomy (RP) for localized prostate cancer". The aim of this project is to assess the effectiveness of this program by comparing the sexual quality of life 1 year after surgery between patients participating and those who do not.


Description:

80% of patients undergoing radical prostatectomy report urinary incontinence and erectile dysfunction [Johanssen et al. 2011. Scandinavian Prostate Cancer Group Study]. In the West Indies, the incidence of prostate cancer is one of the highest in the world (World-standardized incidence in Martinique is 164.5 versus 88.8 per 100,000 person-years in Metropolitan France). Over 2007-2014 an average 530 new cases of prostate cancer were diagnosed each year in Martinique, representing 55% of all male cancers [Regional estimates report Public Health France, January 2018]. The prostate is a symbol of male vulnerability [French Association of Urology-Global Market Research and Public Opinion Specialist, 2006]. For other authors, virility is above all a cultural representation, and the "crisis of virility", a recomposition of male identity. Surgery on a sexual organ can alter body image and masculinity. According to Colson et al., patients treated for prostate cancer and their partners clearly place sex in first place in the importance of quality of life domains.


Recruitment information / eligibility

Status Recruiting
Enrollment 136
Est. completion date March 31, 2025
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men diagnosed with localized prostate cancer and consulting in the urology department of Mangot Vulcin site of the Martinique University Hospital - Patients newly diagnosed for prostate cancer and who will benefit from radical prostatectomy (regardless the technique : laparotomy, laparoscopy or robot-assisted micro-invasive surgery) - Fluent in French or Creole - Patients who give consent - Patients affiliated to social security Exclusion Criteria: - Patients diagnosed with another tumor - Person under legal protection

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Oncosexology program
Thematic workshops throughout the year

Locations

Country Name City State
Martinique Centre Hospitalier Universitaire de Martinique Fort-de-France

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Center of Martinique

Country where clinical trial is conducted

Martinique, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of sexual Quality of Life: Questionnaire Administration of sexual of life questionnaire (SEAR for self-esteem and couple relationship) Before the radical prostatectomy
Primary Evaluation of sexual function: Questionnaire Administration of sexual function questionnaire (IIEF-type validated questionnaires) Before the radical prostatectomy
Primary Evaluation of sexual Quality of Life: Questionnaire Administration of sexual of life questionnaire (SEAR for self-esteem and couple relationship) 1 Month after the radical prostatectomy
Primary Evaluation of sexual function: Questionnaire Administration of sexual function questionnaire (IIEF-type validated questionnaires) 1 Month after the radical prostatectomy
Primary Evaluation of sexual Quality of Life: Questionnaire Administration of sexual of life questionnaire (SEAR for self-esteem and couple relationship) 12 months after the radical prostatectomy
Primary Evaluation of sexual function: Questionnaire Administration of sexual function questionnaire (IIEF-type validated questionnaires) 12 months after the radical prostatectomy
Secondary Evaluation of quality of life in its multidimensional aspect Administration of quality of life questionnaire (EORTC QLC C30 questionnaires) Before the radical prostatectomy
Secondary Evaluation of quality of life for localized forms of prostate cancer Administration of QLQ-PR25 questionnaire (specific module intended for localized forms of prostate cancer. It is complementary to QLQ-C30 and better suited to measure the side effects of treatment.) Before the radical prostatectomy
Secondary Evaluation of quality of life in its multidimensional aspect Administration of quality of life questionnaire (EORTC QLC C30 questionnaires) 12 Month after the radical prostatectomy
Secondary Evaluation of quality of life for localized forms of prostate cancer Administration of QLQ-PR25 questionnaire ((specific module intended for localized forms of prostate cancer. It is complementary to QLQ-C30 and better suited to measure the side effects of treatment.) 12 Month after the radical prostatectomy
See also
  Status Clinical Trial Phase
Recruiting NCT04964271 - Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
Completed NCT02546908 - A Registry of Participants With Prostate Cancer in Asia
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT01683994 - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT04838613 - Study of Diagnostic Performance of [18F]CTT1057 in BCR Phase 3
Completed NCT02364531 - A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Completed NCT01929655 - Japanese BAY88-8223 Monotherapy Phase II Study Phase 2
Active, not recruiting NCT05022849 - A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants Phase 1
Completed NCT03261999 - Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer Phase 3
Terminated NCT04907227 - Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension Phase 3
Active, not recruiting NCT03587285 - A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT02217566 - Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy Phase 2
Not yet recruiting NCT04101305 - Measurement of Circulating Tumor Cells in Prostate Cancer
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Withdrawn NCT02905201 - A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) N/A
Terminated NCT03066154 - Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer Phase 1
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Terminated NCT01420965 - Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer Phase 2
Completed NCT01441713 - Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer N/A